`
`
`
`
`
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF DELAWARE
`
`
`FRESENIUS KABI USA, LLC,
`
`
`
`
`
`v.
`
`Plaintiff,
`
`B. BRAUN MEDICAL INC.
`
`Defendant.
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`Civil Action No. _________
`
`COMPLAINT
`
`Fresenius Kabi USA, LLC (“Fresenius”) brings this action for patent infringement
`
`against Defendant B. Braun Medical Inc. (B. Braun”).
`
`1.
`
`This is an action by Fresenius against B. Braun for infringement of United States
`
`Patent No. 8,476,010 (“the ʼ010 patent”). This action arises out of B. Braun’s filing of an
`
`Abbreviated New Drug Application (“ANDA”) seeking approval by the United States Food and
`
`Drug Administration (“FDA”) to sell generic versions of Diprivan®, an innovative intravenously
`
`administered sedative and anesthetic, prior to the expiration of the ʼ010 patent.
`
`THE PARTIES
`
`2.
`
`Fresenius is a Delaware limited liability company with its principal place of
`
`business at Three Corporate Drive, Lake Zurich, Illinois 60047. Fresenius Kabi USA, LLC was
`
`formerly known as APP Pharmaceuticals, LLC.
`
`3.
`
`Upon information and belief, Defendant B. Braun is a Pennsylvania corporation
`
`with its principal place of business at 824 Twelfth Avenue, Bethlehem, PA 18018-3524.
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 2 of 9 PageID #: 2
`
`JURISDICTION AND VENUE
`
`Subject Matter Jurisdiction
`
`4.
`
`5.
`
`This action for patent infringement arises under 35 U.S.C. § 271.
`
`This Court has jurisdiction over the subject matter of this action pursuant to 28
`
`U.S.C. §§ 1331, 1338(a), 2201, and 2202.
`
`Personal Jurisdiction Over B. Braun
`
`6.
`
`Upon information and belief, this Court has personal jurisdiction over B. Braun
`
`because B. Braun through its affiliates and/or agents (1) has sought approval from the FDA to
`
`market and sell its proposed generic Diprivan® product throughout the United States, including
`
`in Delaware; (2) conducts business in this Judicial District; and (3) has engaged in continuous
`
`and systematic contacts with Delaware and/or purposefully availed itself of this forum by, among
`
`other things, marketing, making, shipping, using, offering to sell or selling, or causing others to
`
`use, offer to sell, or sell, B. Braun products in this Judicial District, and deriving substantial
`
`revenue from such activities. Upon information and belief, B. Braun utilizes the services of its
`
`registered agent, Corporation Service Company located at 2711 Centerville Rd., Suite 400,
`
`Wilmington, DE 19808, for its sales and marketing in Delaware. Upon information and belief,
`
`Corporation Service Company is a corporation organized and existing under the laws of
`
`Delaware.
`
`7.
`
`Additionally, B. Braun has been sued for patent infringement in this district and
`
`did not contest personal jurisdiction. See Hospira, Inc. v. B. Braun Medical, Inc., C.A. No. 13-
`
`819; see also Rydex Techs. LLC v. B. Braun Medical Inc. et al., C.A. No. 13-663. B. Braun has
`
`also purposefully availed itself of the rights and benefits of this Court by asserting counterclaims
`
`
`
`2
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 3 of 9 PageID #: 3
`
`in lawsuits filed in this Court, and proactively filing suit for patent infringement in this district.
`
`See B. Braun Medical Inc. et al. v. Termuro Medical Corp. et al., CA No. 09-347.
`
`8.
`
`Upon information and belief, B. Braun has agreements with retailers, wholesalers
`
`or distributors providing for the distribution of its products in the State of Delaware.
`
`9.
`
`Upon information and belief, B. Braun has committed, or aided, abetted,
`
`contributed to and/or participated in the commission of the tortious action of patent infringement
`
`that has led to foreseeable harm and injury to Fresenius, which manufactures Diprivan®, for sale
`
`and use throughout the United States, including the State of Delaware.
`
`10.
`
`Upon information and belief, B. Braun has applied for FDA approval to market
`
`and sell a generic version of Diprivan® throughout the United States, including in Delaware.
`
`11.
`
`On February 24, 2016, B. Braun sent a letter to Fresenius, a Delaware Limited
`
`Liability Company, stating that it had filed ANDA No. 207929 seeking FDA approval to market
`
`a generic Diprivan® product prior to the expiration of the ’010 patent.
`
`12.
`
`Upon information and belief, B. Braun will market, sell, and offer for sale its
`
`proposed generic version of Diprivan® in the State of Delaware following FDA approval of that
`
`product.
`
`13.
`
`Upon information and belief, as a result of B. Braun’s marketing, selling, or
`
`offering for sale of its generic version of Diprivan® in the State of Delaware, Fresenius will lose
`
`sales of Diprivan® and be injured in the State of Delaware.
`
`14.
`
`Upon information and belief, B. Braun’s systematic and continuous business
`
`contacts within Delaware render it at home in Delaware.
`
`15.
`
`Upon information and belief, this Court has personal jurisdiction over B. Braun
`
`for the reasons stated herein, including, inter alia, B. Braun’s activities in the forum, activities
`
`
`
`3
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 4 of 9 PageID #: 4
`
`directed at the forum, significant contacts with the forum, and consent, all of which render B.
`
`Braun at home in the forum. Personal jurisdiction is proper at least under Acorda Therapeutics
`
`Inc. v. Mylan Pharms Inc., No. 2015-1456, 2016 WL 1077048 (Fed. Cir. 2016).
`
`Venue
`
`16.
`
`Venue is proper in this district under 28 U.S.C. § 1391 and 1400(b).
`
`The Patent-in-Suit: United States Patent No. 8,476,010
`
`BACKGROUND
`
`17.
`
`The ʼ010 patent, entitled “Propofol Formulations with Non-Reactive Container
`
`Closures,” was duly and lawfully issued on July 2, 2013 to inventors Neil P. Desai, Andrew
`
`Yang, and Sherry Xiaopei Ci. The named inventors assigned the ʼ010 patent to APP
`
`Pharmaceuticals, LLC, which later changed its name to Fresenius Kabi USA, LLC.
`
`Accordingly, Fresenius is the owner of all rights, title, and interest in the ʼ010 patent. The ʼ010
`
`patent is listed in the FDA publication “Approved Drug Products with Therapeutic Equivalence
`
`Evaluations,” commonly referred to as “The Orange Book” (“Orange Book”) with respect to
`
`Diprivan®. The ʼ010 patent will expire on June 1, 2025. A true and accurate copy of the ʼ010
`
`patent is attached hereto as Exhibit A.
`
`The Diprivan® Drug Product
`
`18.
`
`Fresenius currently sells, promotes, distributes, and markets Diprivan® (propofol)
`
`injectable emulsion in the United States.
`
`19.
`
`Diprivan® is indicated, generally speaking, for the induction and maintenance of
`
`general anesthesia and sedation in certain patient populations.
`
`20.
`
`Fresenius holds an approved New Drug Application (“NDA”) No. 19627 under
`
`Section 505(b) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(a) in connection
`
`
`
`4
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 5 of 9 PageID #: 5
`
`with the Diprivan® 1% (propofol) injectable emulsion product containing 10 mg propofol per 1
`
`ml of emulsion.
`
`The B. Braun ANDA
`
`21.
`
`B. Braun filed with the FDA an ANDA under 21 U.S.C. § 355(j) seeking approval
`
`to manufacture, use, offer for sale, sell in and import into the United States a propofol injectable
`
`emulsion containing 10mg propofol per 1 ml of emulsion formulation, in 20 mL, 50 mL and 100
`
`mL vials, that B. Braun asserts is a generic copy of Diprivan® (“B. Braun’s generic Diprivan®
`
`products”) prior to the expiration of the ʼ010 patent.
`
`22.
`
`23.
`
`The FDA assigned the B. Braun ANDA the number 207929.
`
`B. Braun filed with the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(II), a
`
`certification that U.S. Patent Nos. 5,714,520; 5,731,355; 5,731,356 and 5,908,869 (“the ’520,
`
`’355, ’356, and ’869 patents”) have expired.
`
`24.
`
`B. Braun filed with the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), a
`
`certification alleging that the claims of the ʼ010 patent are invalid, unenforceable and/or would
`
`not be infringed by the manufacture, use, importation, sale or offer for sale of B. Braun’s generic
`
`Diprivan® products (“B. Braun’s Paragraph IV Certification”). B. Braun notified Fresenius of
`
`this certification, in a letter dated February 24, 2016 sent by U.S. Mail (“B. Braun Notice
`
`Letter”).
`
`25.
`
`In the B. Braun Notice Letter, B. Braun offered Fresenius confidential access to
`
`ANDA No. 207929 on terms and conditions set forth in an attached “Offer of Confidential
`
`Access” (“OCA”). The initial OCA provided by B. Braun contained various terms and
`
`conditions, several of which went above and beyond protections typically afforded in a
`
`protective order. Fresenius and B. Braun proceeded to negotiate the provisions of the OCA, and
`
`
`
`5
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 6 of 9 PageID #: 6
`
`a final version of the OCA was executed by both parties on March 25, 2015.
`
`26.
`
`On April 4, 2016, Fresenius received certain abbreviated portions of ANDA No.
`
`207929 from B. Braun, pursuant to the OCA.
`
`27.
`
`Given the 45-day statutory deadline to file suit set forth in 21 U.S.C.
`
`§ 355(j)(5)(B)(iii) and due to the limited information Fresenius has received from B. Braun to
`
`date, Fresenius turns to the judicial process and the aid of discovery to obtain, under appropriate
`
`judicial safeguards, such information as is required to further confirm its allegations of
`
`infringement and to present to the Court evidence that B. Braun’s generic Diprivan® products fall
`
`within the scope of one or more claims of the ’010 patent.
`
`COUNT I FOR INFRINGEMENT OF U.S. PATENT NO. 8,476,010 BY B. BRAUN
`
`28.
`
`The allegations of paragraphs 1-27 are realleged and incorporated herein by
`
`reference.
`
`29.
`
`The use of B. Braun’s generic Diprivan® products is covered by one or more
`
`claims of the ʼ010 patent.
`
`30.
`
`The commercial manufacture, use, offer for sale, sale, marketing, distribution,
`
`and/or importation of B. Braun’s generic Diprivan® products would infringe one or more claims
`
`of the ʼ010 patent.
`
`31.
`
`B. Braun has infringed the ʼ010 patent by submitting and maintaining the B.
`
`Braun ANDA before the FDA seeking approval to market B. Braun’s generic Diprivan® products
`
`containing propofol before the expiration of the ʼ010 patent.
`
`32.
`
`B. Braun was aware of the ʼ010 patent when engaging in these knowing and
`
`purposeful activities and was aware that filing B. Braun’s ANDA with the Paragraph IV
`
`Certification with respect to the ʼ010 patent constituted an act of infringement of the ’010 patent.
`
`
`
`6
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 7 of 9 PageID #: 7
`
`33.
`
`Upon information and belief, B. Braun intends to engage in the manufacture, use,
`
`offer for sale, sale, marketing, distribution, and/or importation of B. Braun’s generic Diprivan®
`
`products immediately and imminently upon approval of the B. Braun ANDA.
`
`34.
`
`The foregoing actions by B. Braun constitute and/or would constitute
`
`infringement of the ʼ010 patent.
`
`35.
`
`Upon information and belief, B. Braun acted without a reasonable basis for
`
`believing that it would not be liable for infringing the ʼ010 patent, actively inducing infringement
`
`of the ʼ010 patent, and/or contributing to the infringement by others of the ʼ010 patent.
`
`36.
`
`Fresenius will be substantially and irreparably harmed by B. Braun’s infringing
`
`activities unless the Court enjoins those activities. Fresenius will have no adequate remedy at
`
`law if B. Braun is not enjoined from the commercial manufacture, use, offer to sell, sale in, and
`
`importation into the United States of B. Braun’s generic Diprivan® products.
`
`37.
`
`B. Braun’s activities render this case an exceptional one, and Fresenius is entitled
`
`to an award of its reasonable attorney fees under 35 U.S.C. § 285.
`
`PRAYER FOR RELIEF
`
`
`
`WHEREFORE, Fresenius respectfully requests the following relief:
`
`a.
`
`A judgment that B. Braun’s submission of the B. Braun’s ANDA No. 207929
`
`infringes one or more claims of the ʼ010 patent and that the making, using, offering to sell, or
`
`selling in the United States, or importing into the United States of B. Braun’s generic Diprivan®
`
`products prior to the expiration of the ʼ010 patent will infringe of one or more claims of the
`
`patent;
`
`b.
`
`An Order pursuant to 35 U.S.C. § 271(e)(4)(A) providing that the effective date of
`
`any FDA approval of B. Braun’s ANDA No. 207929 seeking approval to manufacture, use, offer
`
`
`
`7
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 8 of 9 PageID #: 8
`
`for sale, sell in and import into the United States a propofol injectable emulsion containing 10mg
`
`propofol per 1 ml of emulsion formulation, in 20 mL, 50 mL and 100 mL vials, or any product or
`
`compound the use of which infringes the ʼ010 patent, shall be a date that is not earlier than the
`
`expiration of the patent;
`
`c.
`
`An Order permanently enjoining Defendants and all persons acting in concert
`
`with Defendants from commercially manufacturing, using, offering for sale, selling, marketing,
`
`distributing, or importing B. Braun’s generic Diprivan® products, or any other product or
`
`compound the use of which infringes the ʼ010 patent, or inducing or contributing to the
`
`infringement of the ʼ010 patent until after the expiration of the patent;
`
`d.
`
`An Order enjoining Defendants and all persons acting in concert with Defendants
`
`from seeking, obtaining, or maintaining approval of the B. Braun’s ANDA No. 207929 before
`
`the expiration of the ʼ010 patent;
`
`e.
`
`An award of Plaintiff’s damages or other monetary relief to compensate Plaintiff
`
`if Defendants engage in the commercial manufacture, use, offer to sell, sale or marketing or
`
`distribution in, or importation into the United States of Defendants’ generic Diprivan® products,
`
`or any product or compound the use of which infringes the ʼ010 patent, prior to the expiration of
`
`the patent in accordance with 35 U.S.C. § 271(e)(4)(C);
`
`f.
`
`A judgment that this is an exceptional case and awarding Plaintiff its attorneys’
`
`fees under 35 U.S.C. § 285;
`
`An award of Plaintiff’s reasonable costs and expenses in this action; and
`
`An award of any further and additional relief to Plaintiff as this Court deems just
`
`g.
`
`h.
`
`and proper.
`
`
`
`8
`
`
`
`Case 1:16-cv-00250-RGA Document 1 Filed 04/11/16 Page 9 of 9 PageID #: 9
`
`
`Dated: April 11, 2016
`
`
`
`
`
`
`
`
`Of Counsel:
`
`Daryl L. Wiesen
`John T. Bennett
`Sam Sherry
`GOODWIN PROCTER LLP
`Exchange Place
`53 State Street
`Boston, MA 02109
`(617) 570-1000
`(617) 523-1231 (fax)
`DWiesen@goodwinprocter.com
`JBennett@goodwinprocter.com
`SSherry@goodwinprocter.com
`
`Krupa Parikh
`GOODWIN PROCTER LLP
`901 New York Ave. NW
`Washington, D.C. 20009
`(202) 346-4000
`(202) 346-4444 (fax)
`KParikh@goodwinprocter.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`FARNAN LLP
`
`
`/s/ Brian E. Farnan
`Brian Farnan(Bar No. 4089)
`Michael J. Farnan (Bar No. 5165)
`919 North Market Street
`12th Floor
`Wilmington, DE 19801
`Phone: 302-777-0300
`Fax: 302-777-0301
`bfarnan@farnanlaw.com
`mfarnan@farnanlaw.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Attorneys for Plaintiff
`Fresenius Kabi USA, LLC
`
`
`9
`
`